Observing treatment effects in patients with AL-CM

Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy

Observational Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT04924998

This study is looking at how well current treatments work for people with AL-CM by following their experiences over time.

Quick facts

Study typeObservational
Enrollment400 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University Academic / other
Locations1 site (Hangzhou, Zhejiang)
Trial IDNCT04924998 on ClinicalTrials.gov

What this trial studies

This observational study focuses on patients diagnosed with Immunoglobulin Light Amyloidosis Cardiomyopathy (AL-CM) to monitor the effects of current treatments and conduct long-term follow-up. Participants aged 18 to 90 years will be recruited from the Second Affiliated Hospital of Zhejiang University School of Medicine. The study aims to gather data on treatment outcomes and patient experiences over time. By observing these patients, researchers hope to gain insights into the effectiveness of existing therapies for AL-CM.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-90 diagnosed with AL-CM who can understand and cooperate with the study requirements.

Not a fit: Patients who are unable to understand the study or unwilling to provide informed consent may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of treatment effectiveness for patients with AL-CM, potentially leading to improved management strategies.

How similar studies have performed: While this approach is observational, similar studies in the past have provided valuable insights into treatment effects for other conditions, suggesting potential for meaningful findings.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
* Patients have the ability to understand the test, can cooperate with investigators.

Exclusion Criteria:

* Unable to understand or unwilling to fill in informed consent forms or follow visitors

Where this trial is running

Hangzhou, Zhejiang

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Immunoglobulin Light Amyloidosis Cardiomyopathy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.